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ABSTRACT
Background The authors consider whether differences
in stage at diagnosis could explain the variation in lung
cancer survival between six developed countries in
2004–2007.
Methods Routinely collected population-based data
were obtained on all adults (15–99 years) diagnosed
with lung cancer in 2004–2007 and registered in
regional and national cancer registries in Australia,
Canada, Denmark, Norway, Sweden and the UK. Stage
data for 57 352 patients were consolidated from various
classiﬁcation systems. Flexible parametric hazard models
on the log cumulative scale were used to estimate net
survival at 1 year and the excess hazard up to
18 months after diagnosis.
Results Age-standardised 1-year net survival from
non-small cell lung cancer ranged from 30% (UK) to
46% (Sweden). Patients in the UK and Denmark had
lower survival than elsewhere, partly because of a
more adverse stage distribution. However, there were
also wide international differences in stage-speciﬁc
survival. Net survival from TNM stage I non-small cell
lung cancer was 16% lower in the UK than in
Sweden, and for TNM stage IV disease survival was
10% lower. Similar patterns were found for small cell
lung cancer.
Conclusions There are comparability issues when
using population-based data but, even given these
constraints, this study shows that, while differences in
stage at diagnosis explain some of the international
variation in overall lung cancer survival, wide
disparities in stage-speciﬁc survival exist, suggesting
that other factors are also important such as
differences in treatment. Stage should be included in
international cancer survival studies and the
comparability of population-based data should be
improved.
INTRODUCTION
Lung cancer remains the leading cause of cancer
death worldwide.1 Survival has not improved
greatly over the past three decades, and remains
low for patients with all but the least invasive
tumours.2 Wide international inequalities in lung
cancer survival remain apparent,3 4 even between
European countries.5
Governments monitor the implementation and
efﬁcacy of their cancer plans by comparing survival
outcomes with those achieved in other countries
with similar levels of economic development.6 The
highest survival among such countries is a bench-
mark against which progress can be monitored,
representing what could be attained with optimal
treatment and public awareness.7 The International
Cancer Benchmarking Partnership (ICBP), a con-
sortium of clinicians, epidemiologists and policy
makers, has described lung cancer survival
differences between six developed countries in
1995–2007.8
Understanding why these survival differences
occur will facilitate policy designed to bring survival
up to the highest international standard. Stage at
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Key messages
What is the key question?
▸ Do differences in stage at diagnosis explain
wide international differences in lung cancer
survival?
What is the bottom line?
▸ Differences in stage at diagnosis explain some
of the international variation in lung cancer
survival, but wide disparities in stage-speciﬁc
survival suggest that other factors such as
treatment are also important.
Why read on?
▸ This is the ﬁrst international population-based
study of lung cancer survival by stage at
diagnosis and includes nearly 60 000 patients.
▸ We describe how far stage explains
international inequalities in lung cancer
survival.
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diagnosis is an important prognostic factor, and international
population-based studies suggest that differences in stage explain
some of the survival variation for several cancers, including the
ICBP study for ovarian cancer.9–12 Few such studies exist for lung
cancer, although stage explains some of the survival differences
between Nordic countries13 and within countries over time.2 In
this study, using population-based data, we investigate whether
lung cancer survival differences may be attributable to differences
in stage at diagnosis, reﬂecting delays in diagnosis or differences
in staging procedures, or to differences in stage-speciﬁc survival
which could indicate differences in treatment, staging or
comorbidity.
Clinical trials are the gold standard for testing the efﬁcacy of
new therapies, but they usually exclude elderly, frail and socially
marginalised patients. Trials cannot be used for international
comparisons of the effectiveness of entire health systems to
underpin public health policy: population-based data on the sur-
vival of all patients are required.
METHODS
Data were originally collected for patients diagnosed during
1995–2007 and followed up to the end of 2007 in six countries:
Norway, Denmark, the UK (Northern Ireland, Wales and
England), Australia (New South Wales and Victoria), Canada
(Alberta, British Columbia, Manitoba and Ontario) and Sweden
(clinical database of the Uppsala-Örebro and Stockholm-Gotland
health regions). Adults (15–99 years) diagnosed with an invasive
primary malignant tumour of the lung or bronchus (ICD-10
C34.0-C34.9) were included. Patients whose tumour registration
was made from a death certiﬁcate only were excluded. Details of
inclusion criteria and quality control have been published
elsewhere.8
Analyses were restricted to the period 2004–2007 (232 278
patients) when stage data were more complete, and further to
registries where at least 50% of patients were staged, thereby
excluding Ontario, Victoria, Wales and six of the eight regional
registries in England. A total of 57 352 patients were ﬁnally
included in the analyses.
We requested stage data in three separate ﬁelds on the extent
of the tumour (T), the degree of nodal involvement (N) and the
presence of metastases (M), coded to the TNM classiﬁcation.14
We prioritised pathological T and N and clinical M where both
clinical and pathological data were available. Norway and New
South Wales provided a locally-deﬁned stage classiﬁed as ‘local,
regional, distant’.
In order to include Norway and New South Wales in the
comparisons, we mapped the TNM system used in the four
other countries to the US Surveillance, Epidemiology and End
Results Summary Stage 2000 classiﬁcation (SEER),15 which is
similar to both the Norwegian and the New South Wales
‘localised, regional, distant’ classiﬁcations, but better documen-
ted and more widely known.16 This mapping was straightfor-
ward where we had information on each of T, N and M, but
it was not possible for England which only provided a
grouped TNM stage (I–IV). We therefore present two sets of
analyses: one in which stage is categorised to the TNM classi-
ﬁcation system, which may be more relevant for clinicians but
excludes Australia and Norway, and another in which stage is
classiﬁed as ‘localised, regional, distant’ (SEER), which
excludes England.
We examined non-small cell (NSCLC) and small cell lung
cancer (SCLC) separately because of their different aetiology
and clinical behaviour. NSCLC represents over 80% of lung
cancers, and we included non-microscopically veriﬁed tumours
in this group. NSCLCs grow more slowly and are generally
more amenable to treatment, whereas SCLC is more aggressive
although short-term survival can be extended with
chemotherapy.
Statistical analyses
We estimated net survival and its mortality equivalent (the
excess hazard) using a ﬂexible parametric model implemented in
the Stata command stpm217 (StataCorp LP, College Station,
Texas, USA, web appendix para 1). Net survival (or excess
hazard) is the survival (or the mortality) of cancer patients after
background mortality in the general population has been taken
into account. Background mortality was taken from life tables
speciﬁc to sex, single year of age, region of residence and year
of death.8
Analysis was ﬁrst stratiﬁed by stage at diagnosis; age at diag-
nosis and country of residence were included as covariates and
their effects allowed to vary with time since diagnosis.
Non-linear effects of continuous covariates and time-dependent
Table 1 Sex of patients, proportion not microscopically verified and histological subtypes
Australia* Canada† Denmark Norway Sweden‡ UK§
Number of patients¶ 12233 9805 16058 9445 5246 26 243
% Men 62.2 52.9 53.6 59.1 52.3 60.1
% Without microscopic verification** 14.4 18.2 13.5 10.1 5.2 26.0
Histological subtype as % of microscopically verified tumours (ICD-O-3 code)
Adenocarcinoma (8140-8576) 35.6 41.0 35.4 36.5 44.8 25.2
Squamous cell (8050-8084) 20.0 20.9 22.1 22.6 21.8 27.6
Large cell (8012-8035, 8046) 26.7 20.0 14.8 17.2 15.6 23.3
Small cell (8040-8045) 12.9 14.4 17.1 18.0 13.6 16.7
Other†† 4.9 3.7 10.7 5.8 4.2 7.1
*Australia: New South Wales.
†Canada: Alberta and Manitoba.
‡Sweden: Uppsala-Örebro and Stockholm-Gotland health regions.
§UK (TNM analysis): West Midlands Cancer Intelligence Unit and the Eastern Cancer Registry and Information Centre in England and Northern Ireland; UK (SEER analysis): Northern
Ireland.
¶This table refers to patients included in the TNM analyses for Canada, Denmark, Sweden and the UK, and to the patients included in SEER analyses for Australia and Norway.
**Includes patients with morphological verification but missing morphology (ICD-O-3 code 9990 and above).
††Carcinomas (8010-8011), basal cell (8090-8110), transitional cell (812-813), sarcomas (8800-8921), other, Not Otherwise Specified (8000-8005, 8580-8790, 8930-9989).
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Table 2 Number of patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) diagnosed during 2004–2007: country and stage at diagnosis (TNM and SEER Summary
Stage 2000), before and after imputation
TNM stage SEER Summary Stage 2000
Non-small cell Small cell Non-small cell Small-cell
% % % %
Stage Number¶
Mean age
at
diagnosis Observed
After
imputation Number¶
Mean age
at
diagnosis Observed
After
imputation Stage Number¶
Mean age
at
diagnosis Observed
After
imputation Number¶
Mean age
at
diagnosis Observed
After
imputation
Australia* All
patients
10878 70.5 1355 69.1
Missing
stage
2541 73.4 23.4 252 69.2 18.6
Localised 2500 70.8 30.0 30.8 249 68.2 22.6 23.8
Regional 1878 69.0 22.5 22.8 178 69.3 16.1 16.6
Distant 3959 69.3 47.5 46.4 676 69.5 61.3 59.6
Canada† All patients 8648 70.2 1157 67.7 All
patients
8648 70.2 1157 67.7
Missing
stage
485 72.9 5.6 24 72.8 2.1 Missing
stage
568 73.2 6.6 46 70.6 4.0
I 1635 70.6 20.0 20.1 37 70.3 3.3 3.3 Localised 1635 70.6 20.2 20.3 37 70.3 3.3 3.3
II 409 69.3 5.0 5.0 19 66.1 1.7 1.7 Regional 2141 70.9 26.5 26.5 292 67.9 26.3 26.2
III 2155 71.0 26.4 26.4 360 67.7 31.8 31.8 Distant 4304 69.3 53.3 53.1 782 67.3 70.4 70.5
IV 3964 69.3 48.6 48.4 717 67.4 63.3 63.3
Denmark All patients 13681 69.0 2377 67.7 All
patients
13681 69.0 2377 67.7
Missing
stage
1535 74.8 11.2 194 70.6 8.2 Missing
stage
1535 74.8 11.2 194 70.6 8.2
I 1749 69.0 14.4 14.0 63 69.6 2.9 3.7 Localised 1749 69.0 14.4 14.0 63 69.6 2.9 2.9
II 701 68.4 5.8 5.7 36 67.5 1.6 2.2 Regional 2959 68.5 24.4 24.1 333 67.7 15.3 15.1
III 3019 68.2 24.9 24.6 511 67.2 23.4 23.1 Distant 7438 68.0 61.2 61.9 1787 67.4 81.9 82.0
IV 6677 68.1 55.0 55.7 1573 67.5 72.1 71.0
Norway All patients All
patients
7921 70.0 1524 67.8
Missing
stage
Missing
stage
787 73.4 9.9 111 68.1 7.3
I Localised 1256 70.2 17.6 17.7 72 69.4 5.1 5.3
II Regional 2382 69.8 33.4 33.6 372 66.7 26.3 26.6
III Distant 3496 69.3 49.0 48.6 969 68.1 68.6 68.2
IV
Sweden‡ All patients 4570 69.3 676 68.8 All
patients
4570 69.3 676 68.8
Missing
stage
266 74.8 5.8 31 70.7 4.6 Missing
stage
266 74.8 5.8 31 70.7 4.6
I 850 69.0 19.7 19.6 23 69.8 3.6 3.6 Localised 850 69.0 19.7 19.6 23 69.8 3.6 3.5
II 152 70.4 3.5 3.5 8 70.1 1.2 1.3 Regional 1090 70.1 25.3 25.2 116 68.7 18.0 17.9
III 1286 69.6 29.9 29.9 203 68.4 31.5 31.4 Distant 2364 68.4 54.9 55.2 506 68.6 78.4 78.6
IV 2016 68.4 46.8 47.0 411 68.7 63.7 63.7
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effects were modelled with cubic splines. Interactions between
age and country were assessed with the likelihood ratio test.
Final models were selected based on the Akaike Information
Criterion and examination of Martingale residuals (web appen-
dix para 2). Patients were censored 3 years after diagnosis, but
we provide estimates up to 18 months after diagnosis because
model stability requires follow-up beyond the last survival
estimate.18
We ﬁrst treated patients with missing stage as a separate cat-
egory. Multiple imputation by chained equations was then con-
ducted to include patients with missing stage in the analyses
using the Stata command ice19 (web appendix para 3). We ran
the imputation model 15 times and combined the results under
Rubin’s rules.19 We then re-estimated stage-speciﬁc survival
using the 15 imputed datasets by repeating the survival analysis
modelling strategy described above, and compared the range of
survival estimates with the estimates for patients with known
stage.
We present survival estimates by age, stage and country.
All-ages estimates were standardised using stage-speciﬁc weights
based on the age distribution observed across all countries (see
online web appendix, tables 1 and 2).
RESULTS
Descriptive statistics
Men represented between 52.3% (Sweden) and 62.2%
(Australia) of all patients (table 1). In the UK, 26.0% of tumours
were not microscopically veriﬁed compared with 5.2% in
Sweden (table 1). Among microscopically-conﬁrmed tumours,
the percentage of SCLC varied from 12.9% in Australia to
18.0% in Norway. The proportion of adenocarcinomas ranged
from 25.2% (UK) to 44.8% (Sweden). The age distribution at
diagnosis was similar in all countries, with mean age about
70 years (table 2). Patients for whom information on stage at
diagnosis was missing tended to be older (mean age about
73 years). Patients diagnosed at a more advanced stage tended
to be younger than those diagnosed at an earlier stage, and
older patients were more likely to be missing data on stage (see
online web appendix ﬁgure 1).
Stage at diagnosis
The UK had the highest proportion of patients for whom data on
stage (TNM) at diagnosis were missing, both for NSCLC (30.3%
vs 5.6–11.2% elsewhere) and for SCLC (38.4% vs 2.1–8.2%).
The proportion was also relatively high in Australia (SEER), both
for NSCLC (23.4%) and SCLC (18.6%) (table 2).
Lung cancer is generally diagnosed at an advanced stage. For
NSCLC, the proportion with metastatic disease (TNM stage IV)
ranged from 46.8% in Sweden to 55.0% in Denmark, or (SEER
‘distant’) from 47.5% in Australia to 61.2% in Denmark. The
proportion of early stage NSCLC was lowest in Denmark and
the UK.
For SCLC, 72.1% of patients in Denmark had metastatic
disease (TNM stage IV) compared with less than 66% else-
where. For SEER ‘distant’, the proportion ranged from 61.3%
in Australia to around 82% in Denmark and the UK (table 2).
Imputing TNM or SEER stage where it was missing did not
consistently shift stage distribution towards a more or less
advanced stage. The increase in the proportion of TNM stage
IV was 0.2–2.6% for patients with NSCLC (table 2) and −1.1%
to +0.3% for those with SCLC.
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Table 3 One-year net survival (NS, %) overall, age-standardised and age-specific, by stage at diagnosis and country for patients with non-small cell lung cancer diagnosed during 2004–2007
Australia* Canada† Denmark Norway Sweden‡ UK§
NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI
TNM stage
All patients
All ages 41.8 40.7 to 42.8 35.4 34.6 to 36.2 46.1 44.7 to 47.5 28.8 28.3 to 29.4
Age-standardised 41.7 40.9 to 42.5 34.1 33.5 to 34.7 45.5 44.5 to 46.6 29.6 29.1 to 30.0
15–54 50.4 47.9 to 53.0 45.4 43.3 to 47.4 54.2 50.6 to 57.7 41.5 39.6 to 43.5
55–74 44.2 42.9 to 45.5 39.3 38.4 to 40.3 48.0 46.4 to 49.7 32.5 31.7 to 33.2
75–99 36.0 34.5 to 37.5 24.9 23.8 to 26.0 40.7 38.5 to 42.9 22.6 21.8 to 23.3
Stage I
All ages 86.2 84.6 to 87.8 75.0 73.1 to 76.9 88.8 86.7 to 90.9 71.1 69.4 to 72.9
Age-standardised 86.3 85.3 to 87.3 73.3 71.9 to 74.6 88.4 87.0 to 89.8 72.5 71.4 to 73.6
15–54 95.5 94.1 to 96.9 92.4 90.6 to 94.2 94.5 92.1 to 96.8 90.0 88.0 to 92.0
55–74 89.5 88.0 to 91.0 79.7 77.8 to 81.6 89.9 87.9 to 91.8 77.5 75.6 to 79.3
75–99 79.5 76.6 to 82.3 59.8 56.2 to 63.5 85.2 81.6 to 88.8 60.9 58.2 to 63.6
Stage II
All ages 79.0 75.2 to 82.7 60.8 57.1 to 64.5 70.3 63.1 to 77.6 58.6 55.7 to 61.5
Age-standardised 78.5 76.3 to 80.7 59.1 56.8 to 61.5 70.7 66.8 to 74.7 59.8 57.9 to 61.7
15–54 89.7 86.6 to 92.8 79.0 73.6 to 84.4 88.7 83.2 to 94.1 79.9 74.5 to 85.2
55–74 82.4 79.0 to 85.9 64.9 61.1 to 68.8 75.5 69.0 to 82.1 65.3 62.1 to 68.5
75–99 69.0 63.6 to 74.5 46.0 40.8 to 51.2 58.2 48.6 to 67.8 45.5 41.6 to 49.4
Stage III
All ages 43.2 41.3 to 45.2 45.0 43.3 to 46.8 47.1 44.5 to 49.8 34.4 33.1 to 35.8
Age-standardised 44.0 42.5 to 45.4 42.8 41.5 to 44.1 46.4 44.5 to 48.4 35.3 34.3 to 36.3
15–54 53.5 48.1 to 58.9 57.8 53.6 to 61.9 55.4 48.3 to 62.4 44.4 40.2 to 48.6
55–74 49.3 46.7 to 51.8 49.4 47.4 to 51.5 52.5 49.4 to 55.7 39.6 37.9 to 41.4
75–99 33.2 30.4 to 35.9 30.8 28.0 to 33.5 35.7 31.8 to 39.6 26.3 24.6 to 28.1
Stage IV
All ages 16.8 15.7 to 17.8 21.4 20.5 to 22.3 25.9 24.1 to 27.7 15.5 14.7 to 16.2
Age-standardised 16.8 16.0 to 17.6 20.8 20.1 to 21.5 25.6 24.3 to 27.0 15.9 15.3 to 16.4
15–54 24.0 21.0 to 27.1 27.4 24.9 to 29.8 31.1 26.3 to 35.9 24.5 22.0 to 27.1
55–74 17.5 16.1 to 18.8 23.5 22.4 to 24.6 27.1 24.9 to 29.2 17.1 16.1 to 18.0
75–99 13.2 11.7 to 14.6 14.4 13.2 to 15.7 21.7 19.0 to 24.5 10.9 9.9 to 11.8
Missing stage
All ages 42.2 38.4 to 46.0 19.2 17.3 to 21.0 34.4 29.0 to 39.9 20.6 19.7 to 21.5
Age-standardised 38.7 35.4 to 42.0 19.6 18.1 to 21.1 34.7 30.4 to 39.1 20.6 19.9 to 21.2
15–54 88.4 82.4 to 94.4 40.5 31.7 to 49.3 49.7 31.0 to 68.5 42.1 38.0 to 46.1
55–74 40.8 34.4 to 47.2 21.3 18.4 to 24.1 40.2 31.5 to 48.9 23.7 22.4 to 25.0
75–99 33.2 28.0 to 38.5 15.8 13.6 to 18.1 29.7 23.1 to 36.3 16.0 14.9 to 17.0
Continued
W
alters
S,etal.Thorax
2013;68:551
–564.doi:10.1136/thoraxjnl-2012-202297
555
Lung
cancer
Table 3 Continued
Australia* Canada† Denmark Norway Sweden‡ UK§
NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI
SEER Summary Stage 2000
All patients
All ages 41.8 40.9 to 42.7 41.8 40.8 to 42.8 35.4 34.6 to 36.2 38.4 37.4 to 39.5 46.0 44.6 to 47.5 30.4 28.8 to 31.9
Age-standardised 42.4 41.7 to 43.1 42.0 41.3 to 42.8 34.6 34.0 to 35.2 38.5 37.7 to 39.3 45.8 44.7 to 46.8 30.9 29.7 to 32.0
15–54 53.5 51.1 to 56.0 50.1 47.5 to 52.7 45.0 43.0 to 47.1 49.8 46.9 to 52.7 53.8 50.3 to 57.4 46.1 41.3 to 50.9
55–74 46.4 45.3 to 47.6 44.2 42.9 to 45.4 39.2 38.3 to 40.2 42.9 41.6 to 44.2 47.9 46.3 to 49.6 32.5 30.6 to 34.4
75–99 32.8 31.5 to 34.0 36.2 34.7 to 37.6 25.1 24.0 to 26.2 29.0 27.6 to 30.5 40.8 38.6 to 42.9 24.3 22.2 to 26.4
Localised
All ages 63.2 61.5 to 64.9 85.8 84.2 to 87.5 73.9 71.9 to 75.8 74.9 72.6 to 77.1 88.3 86.2 to 90.5 67.5 62.9 to 72.1
Age-standardised 64.4 63.3 to 65.5 86.1 85.1 to 87.0 72.5 71.3 to 73.7 74.9 73.6 to 76.2 87.8 86.5 to 89.0 68.1 65.7 to 70.6
15–54 83.8 81.3 to 86.2 94.1 93.1 to 95.2 87.4 85.5 to 89.3 89.1 87.2 to 91.0 95.4 94.2 to 96.6 85.9 82.7 to 89.0
55–74 71.4 69.6 to 73.2 89.7 88.3 to 91.0 78.3 76.5 to 80.1 80.3 78.3 to 82.3 90.8 89.1 to 92.6 74.1 70.0 to 78.2
75–99 48.5 46.1 to 50.9 78.5 76.0 to 80.9 60.5 57.5 to 63.4 63.4 60.1 to 66.6 81.7 78.5 to 85.0 55.8 50.0 to 61.6
Regional
All ages 52.8 50.7 to 54.9 53.6 51.5 to 55.7 51.2 49.4 to 53.0 47.4 45.4 to 49.4 54.2 51.3 to 57.1 46.5 42.4 to 50.7
Age-standardised 52.3 51.1 to 53.6 55.2 54.1 to 56.4 50.0 48.9 to 51.1 47.6 46.4 to 48.7 54.7 53.2 to 56.3 46.3 44.1 to 48.5
15–54 67.1 64.1 to 70.2 69.7 67.1 to 72.4 64.9 62.1 to 67.6 63.1 60.2 to 66.1 68.9 65.6 to 72.3 61.6 57.0 to 66.1
55–74 58.4 56.2 to 60.6 61.2 59.0 to 63.3 56.1 54.2 to 58.0 54.1 52.1 to 56.2 60.9 58.1 to 63.7 52.2 48.0 to 56.3
75–99 37.8 35.2 to 40.4 39.9 37.4 to 42.4 36.3 34.0 to 38.6 32.9 30.6 to 35.3 40.3 36.9 to 43.7 32.6 28.1 to 37.1
Distant
All ages 17.6 16.5 to 18.6 18.5 17.4 to 19.6 22.9 22.0 to 23.8 18.3 17.1 to 19.5 27.3 25.6 to 28.9 18.6 16.4 to 20.8
Age-standardised 17.9 17.1 to 18.7 18.7 17.9 to 19.5 22.4 21.8 to 23.1 18.5 17.7 to 19.4 27.1 25.9 to 28.4 18.3 16.7 to 20.0
15–54 30.1 26.8 to 33.4 25.0 22.1 to 28.0 29.3 27.0 to 31.7 26.3 22.8 to 29.8 31.9 27.4 to 36.4 25.1 18.9 to 31.4
55–74 19.6 18.2 to 21.0 19.4 18.0 to 20.7 25.1 24.0 to 26.2 20.6 19.1 to 22.2 29.0 26.9 to 31.0 19.3 16.8 to 21.9
75–99 10.1 8.9 to 11.4 15.0 13.5 to 16.5 15.6 14.3 to 16.8 12.1 10.6 to 13.5 22.3 19.8 to 24.8 14.3 11.2 to 17.5
Missing stage
All ages 45.8 44.0 to 47.7 42.3 38.6 to 45.9 19.3 17.4 to 21.2 42.2 38.9 to 45.4 35.0 29.5 to 40.5 23.2 21.0 to 25.4
Age-standardised 45.6 44.2 to 47.0 40.2 37.1 to 43.2 19.9 18.4 to 21.5 41.8 39.3 to 44.4 35.5 31.2 to 39.9 23.1 21.4 to 24.8
15–54 61.0 55.2 to 66.8 88.5 83.0 to 94.0 40.5 31.6 to 49.4 72.1 62.3 to 82.0 50.0 31.2 to 68.7 55.5 47.1 to 63.8
55–74 50.4 47.9 to 52.9 42.9 37.1 to 48.7 21.8 18.9 to 24.7 49.7 45.1 to 54.3 41.0 32.3 to 49.8 24.3 21.3 to 27.3
75–99 39.9 37.5 to 42.4 33.3 28.3 to 38.2 15.7 13.4 to 17.9 32.2 28.0 to 36.4 30.1 23.4 to 36.8 18.6 15.9 to 21.3
*Australia: New South Wales.
†Canada: Alberta and Manitoba.
‡Sweden: Uppsala-Örebro and Stockholm-Gotland health regions.
§UK (TNM analysis): West Midlands Cancer Intelligence Unit Eastern Cancer Registration and Information Centre in England and Northern Ireland; UK (SEER analysis): Northern Ireland.
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Survival from non-small cell lung cancer
Overall age-standardised 1-year net survival from NSCLC
ranged from 30% in the UK to 46% in Sweden (table 3).
Survival was also high (42%) in Australia and Canada and inter-
mediate (34–39%) in Denmark and Norway. Overall estimates
differ slightly between the TNM and SEER analyses because
patients in England were only included in the TNM analyses
(40% of all TNM-staged patients) and Australian and
Norwegian patients were only included in the SEER analyses
(38% of all SEER patients). These exclusions affect the model
results for the other countries.
One-year survival for patients with TNM stage I and II
disease was signiﬁcantly lower in the UK (stage I: 72.5%;
stage II: 59.8%) and Denmark (stage I: 73.3%; stage II:
59.1%) than in Canada (stage I: 86.3%; stage II: 78.5%) and
Sweden (stage I: 88.4%; stage II: 70.7%) (table 3). Survival
was also lower in the UK for stage III (35.3% vs 42.8–46.4%
elsewhere) and stage IV (15.9% vs 20.8–25.6% in Denmark
Figure 1 Age-standardised excess hazard (per 1000 person-years, log scale) from non-small cell lung cancer by stage, country and time since
diagnosis: TNM stage (upper panel) and SEER Summary Stage 2000 (lower panel). Notes: (1) National data are used for Denmark and Norway.
Other countries are represented by regional registries (Australia: New South Wales; Canada: Alberta and Manitoba; Sweden: Uppsala-Örebro and
Stockholm-Gotland health regions; the UK (TNM analysis): West Midlands Cancer Intelligence Unit, the Eastern Cancer Registration and Information
Centre in England and Northern Ireland; the UK (SEER analysis): Northern Ireland). (2) Bubbles are scaled to represent stage distribution at
diagnosis.
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and Sweden). The apparent survival advantage in Canada for
early stage NSCLC was not evident at more advanced stage,
and survival for stage IV disease was 16.8%, similar to that
for patients in the UK.
For TNM stages I–II, the excess hazard in the UK and
Denmark was higher than in Canada and Sweden at all time
points up to 18 months, but the differences were widest soon
after diagnosis, narrowing over the ﬁrst year (ﬁgure 1). The
excess hazard for stages III–IV NSCLC was consistently high in
the UK.
Patients with ‘localised’ NSCLC in Australia had low survival,
but survival for more advanced disease was average (table 3,
ﬁgure 2). The excess hazard for Australian patients with
‘regional’ NSCLC declined more steeply with time than in other
countries (ﬁgure 1). Norwegian patients had average stage-
speciﬁc survival (table 3).
The inclusion of patients with imputed stage made no mater-
ial difference to the survival patterns (ﬁgure 2).
Survival from small cell lung cancer
One-year age-standardised net survival from SCLC ranged
from 24.9% in the UK to 36.6% in Sweden (TNM analyses),
and from 23.1% in the UK to 38.7% in Sweden in the
SEER analysis (table 4). The estimates differ because patients
in England (38% of all patients) were only included in
analyses by TNM stage, while Australian and Norwegian
patients (38% of all patients) were only included in analyses
by SEER stage.
Among patients with early stage SCLC (TNM stages I and II),
survival was lower in the UK (55.9%) and Denmark (64.5%)
than in Canada (71.1%) and Sweden (71.7%) (table 4). The UK
had lower survival among patients with stage III (37.3% vs
47.9–52.2%) and stage IV disease (14.4% vs 17.9–27.6%). The
excess hazard of death for UK patients with stage III SCLC was
very high immediately after diagnosis but became average by
18 months (ﬁgure 3). Among patients with stage IV disease, the
excess hazard in the UK and in Canada was high throughout the
ﬁrst 18 months.
Norway had average survival for patients diagnosed at each
SEER stage, and the excess hazard was generally average through-
out follow-up (ﬁgure 3). Patients in Australia had quite low stage-
speciﬁc survival from SCLC (table 4). The range in the excess
hazard between SEER stages was narrower in Australia than in
other countries throughout follow-up (ﬁgure 3).
Survival estimates including patients with imputed stage were
generally close to those for patients with known stage. The main
exception was for the UK (Northern Ireland only) in the SEER
analyses, where the number of patients was small (ﬁgure 4).
DISCUSSION
Lung cancer survival varied widely between these six wealthy
countries in 2004–2007. Age-standardised 1-year net survival
for NSCLC ranged from 30% in the UK to 46% in Sweden.
Survival was relatively low in Denmark, intermediate in Norway
and high in Australia and Canada. For SCLC, 1-year survival
was 12–16% lower in the UK than in Sweden and Australia and
intermediate elsewhere.
These survival differences are partly explained by differences
in stage at diagnosis. Denmark in particular had a more adverse
stage distribution. However, international differences in survival
were also evident within each stage of disease for both types of
lung cancer: generally low in the UK and high in Sweden.
Denmark had low survival for patients with early stage disease
but average survival for those with more advanced disease
while, in Canada, the comparatively high survival for early
disease was not apparent for patients with more advanced
disease. International differences in stage at diagnosis may arise
because of differences in disease aetiology (which may affect the
aggressiveness of disease), or delays in diagnosis or in the
staging procedures themselves. Stage-speciﬁc survival may also
vary because of differences in the quality of and access to stage-
speciﬁc treatment.
Population-based survival estimates are invaluable for public
health surveillance because they include all patients—young and
old, rich and poor, with early or late disease and with or
without comorbidity—not just the small percentage of younger,
ﬁtter patients typically recruited to clinical trials. This study was
based on 57 352 unselected patients with lung cancer from
population-based registries.
However, using such data requires extensive quality control16
to ensure comparability of stage data. We consider our consoli-
dation of raw data from different staging classiﬁcations to have
been largely successful; the stage distributions by age, survival
and morphology are clinically coherent as well as internally con-
sistent and comparable with previous estimates,20–22 but some
potential for misclassiﬁcation remains. For example, small
Figure 2 Age-standardised 1-year net survival from non-small cell
lung cancer by stage at diagnosis and country using known stage and
imputed stage: TNM stage (upper panel) and SEER Summary Stage
2000 (lower panel). Notes: Australia: New South Wales; Canada:
Alberta and Manitoba; Sweden: Uppsala-Örebro and
Stockholm-Gotland health regions; the UK (TNM analysis): West
Midlands Cancer Intelligence Unit, the Eastern Cancer Registration and
Information Centre in England and Northern Ireland; the UK (SEER
analysis): Northern Ireland.
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Table 4 One-year net survival (NS, %) overall, age-standardised and age-specific, by stage at diagnosis and country for patients with small cell lung cancer diagnosed during 2004–2007
Australia* Canada† Denmark Norway Sweden‡ UK§
NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI
TNM stage
All patients
All ages 30.7 28.3 to 33.0 30.8 29.1 to 32.5 36.1 32.9 to 39.3 24.7 23.3 to 26.1
Age-standardised 30.0 28.0 to 32.1 30.6 29.1 to 32.0 36.6 33.8 to 39.4 24.9 23.7 to 26.1
15–54 44.6 38.1 to 51.0 41.2 36.2 to 46.1 48.9 38.6 to 59.3 33.2 29.1 to 37.3
55–74 32.9 30.1 to 35.8 33.9 31.9 to 36.0 39.2 35.4 to 43.0 27.9 26.2 to 29.6
75–99 17.5 14.0 to 20.9 18.1 15.7 to 20.5 26.0 21.1 to 30.8 14.4 12.5 to 16.2
Stage I and II
All ages 71.7 60.4 to 83.1 65.2 56.5 to 73.9 70.3 56.7 to 83.9 56.0 48.7 to 63.4
Age-standardised 71.1 61.5 to 80.7 64.5 57.1 to 71.9 71.7 59.8 to 83.7 55.9 49.6 to 62.2
15–54 94.9 88.6 to 100.0 82.6 66.9 to 98.4 99.9 99.6 to 100.0 82.2 70.5 to 93.8
55–74 77.2 65.0 to 89.4 71.7 61.8 to 81.5 72.5 55.4 to 89.6 57.3 48.7 to 65.9
75–99 48.6 25.7 to 71.6 44.6 29.3 to 59.9 60.0 38.6 to 81.4 44.9 32.4 to 57.5
Stage III
All ages 48.5 43.8 to 53.1 51.0 46.8 to 55.3 51.6 45.0 to 58.1 36.9 32.8 to 41.0
Age-standardised 47.9 43.9 to 52.0 50.6 47.1 to 54.2 52.2 46.6 to 57.8 37.3 33.9 to 40.7
15–54 71.0 59.6 to 82.3 74.3 66.3 to 82.3 63.0 45.4 to 80.5 50.8 40.5 to 61.0
55–74 51.1 45.6 to 56.7 52.7 47.8 to 57.7 54.7 47.0 to 62.4 42.2 37.3 to 47.1
75–99 29.4 21.9 to 36.9 35.3 28.4 to 42.1 41.6 31.4 to 51.8 18.8 13.1 to 24.5
Stage IV
All ages 18.3 15.8 to 20.8 23.0 21.1 to 24.9 26.8 23.0 to 30.6 14.4 12.7 to 16.2
Age-standardised 17.9 16.1 to 19.8 23.0 21.5 to 24.4 27.6 24.6 to 30.6 14.4 13.1 to 15.8
15–54 31.5 25.6 to 37.4 35.5 31.0 to 39.9 39.4 30.1 to 48.7 19.9 15.8 to 24.0
55–74 18.7 16.1 to 21.3 23.8 21.8 to 25.7 28.6 24.5 to 32.8 14.7 12.9 to 16.5
75–99 10.0 7.1 to 13.0 15.0 12.3 to 17.7 19.5 13.9 to 25.2 11.1 8.7 to 13.6
Missing stage
All ages 20.5 6.1 to 35.0 23.2 17.9 to 28.6 16.9 5.4 to 28.4 24.4 22.3 to 26.6
Age-standardised 23.0 13.6 to 32.4 24.3 20.7 to 27.9 16.8 9.5 to 24.2 24.2 22.4 to 26.1
15–54 Not possible to estimate 38.2 29.2 to 47.2 29.3 14.0 to 44.5 38.2 30.8 to 45.6
55–74 25.7 9.7 to 41.7 27.3 21.3 to 33.3 21.1 7.8 to 34.4 28.0 25.3 to 30.8
75–99 13.3 0.9 to 25.7 14.3 9.4 to 19.2 7.9 0.0 to 16.1 13.7 11.0 to 16.4
SEER Summary Stage 2000
All patients
All ages 37.5 35.0 to 39.9 32.9 30.4 to 35.5 33.4 31.6 to 35.2 33.4 31.2 to 35.5 38.2 34.8 to 41.5 23.9 20.1 to 27.6
Age-standardised 38.6 36.5 to 40.6 32.3 30.2 to 34.4 33.1 31.5 to 34.6 33.3 31.4 to 35.1 38.7 35.8 to 41.5 23.1 19.9 to 26.4
15–54 54.5 48.3 to 60.6 46.7 40.2 to 53.2 43.8 38.8 to 48.9 54.2 48.1 to 60.2 51.2 40.9 to 61.4 34.5 25.5 to 43.6
55–74 41.6 38.6 to 44.5 35.2 32.2 to 38.2 36.4 34.3 to 38.6 37.2 34.4 to 39.9 41.3 37.3 to 45.2 24.3 19.8 to 28.8
75–99 24.8 21.3 to 28.2 19.8 16.1 to 23.5 20.7 18.1 to 23.2 16.7 14.0 to 19.5 28.0 22.9 to 33.0 15.3 9.4 to 21.2
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Table 4 Continued
Australia* Canada† Denmark Norway Sweden‡ UK§
NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI NS (%) 95% CI
Localised
All ages 53.7 48.2 to 59.1 74.4 61.9 to 86.9 60.8 49.8 to 71.7 65.9 55.5 to 76.2 72.4 56.5 to 88.4 43.6 23.7 to 63.5
Age-standardised 53.0 49.0 to 57.0 75.8 67.8 to 83.7 61.7 54.6 to 68.7 65.9 59.1 to 72.6 74.0 64.1 to 83.9 41.2 27.9 to 54.5
15–54 77.2 70.1 to 84.3 90.4 84.1 to 96.6 80.9 72.8 to 89.0 83.8 76.7 to 90.9 90.0 82.6 to 97.4 74.0 58.7 to 89.4
55–74 57.9 52.1 to 63.8 78.6 67.3 to 89.8 65.5 55.0 to 75.9 68.8 58.9 to 78.8 77.1 63.1 to 91.2 44.1 22.7 to 65.5
75–99 35.1 27.3 to 42.8 62.2 44.5 to 79.9 46.5 32.5 to 60.4 52.8 39.1 to 66.5 62.3 41.3 to 83.2 24.3 2.9 to 45.8
Regional
All ages 35.4 29.2 to 41.5 50.6 44.9 to 56.2 54.0 48.6 to 59.5 50.7 45.8 to 55.5 56.6 47.8 to 65.3 51.0 34.0 to 67.9
Age-standardised 37.2 31.8 to 42.6 50.1 45.4 to 54.8 54.1 49.6 to 58.6 49.3 45.1 to 53.4 57.4 50.1 to 64.8 51.9 37.0 to 66.7
15–54 52.1 36.1 to 68.2 74.7 63.2 to 86.2 70.2 59.3 to 81.1 75.2 66.0 to 84.4 71.7 51.1 to 92.2 76.5 41.1 to 100.0
55–74 41.1 33.3 to 48.9 53.9 47.3 to 60.4 56.3 50.2 to 62.4 55.1 49.1 to 61.0 60.2 50.0 to 70.4 59.1 36.4 to 81.8
75–99 19.7 11.1 to 28.2 30.1 21.5 to 38.7 41.6 32.2 to 50.9 25.4 17.5 to 33.2 44.8 31.2 to 58.5 22.0 0.7 to 43.3
Distant
All ages 19.8 17.1 to 22.4 23.4 20.7 to 26.1 28.8 26.8 to 30.7 22.9 20.5 to 25.3 32.1 28.5 to 35.8 14.1 9.6 to 18.6
Age-standardised 20.9 18.5 to 23.3 22.8 20.5 to 25.0 28.4 26.7 to 30.0 23.3 21.2 to 25.4 32.6 29.5 to 35.8 14.0 9.9 to 18.1
15–54 31.3 22.2 to 40.4 37.5 30.2 to 44.7 40.3 34.7 to 45.9 40.1 32.0 to 48.3 38.7 27.4 to 50.0 11.7 4.6 to 18.8
55–74 23.0 19.6 to 26.4 24.4 21.2 to 27.6 31.1 28.8 to 33.5 25.8 22.7 to 28.8 35.5 31.2 to 39.8 14.9 9.8 to 20.0
75–99 10.9 7.6 to 14.2 12.6 8.9 to 16.3 16.2 13.4 to 18.9 11.1 8.4 to 13.7 22.3 16.7 to 27.9 13.4 2.9 to 24.0
Missing stage
All ages 57.8 52.3 to 63.3 26.0 14.4 to 37.7 25.5 19.8 to 31.1 39.0 31.0 to 46.9 17.1 6.1 to 28.2 26.3 20.5 to 32.1
Age-standardised 57.8 53.9 to 61.7 26.8 19.3 to 34.3 26.7 22.7 to 30.7 37.5 32.1 to 42.9 16.9 9.6 to 24.1 25.6 21.4 to 29.7
15–54 75.7 67.9 to 83.5 Not possible to estimate 47.5 35.6 to 59.3 59.3 47.5 to 71.2 32.9 16.7 to 49.1 45.7 34.7 to 56.7
55–74 62.4 56.7 to 68.1 31.7 18.9 to 44.5 30.2 23.6 to 36.8 43.6 35.0 to 52.3 22.0 8.5 to 35.5 29.8 22.9 to 36.7
75–99 44.8 37.6 to 52.0 15.4 5.1 to 25.7 14.4 9.1 to 19.6 21.3 13.0 to 29.6 6.3 0.0 to 13.1 12.9 7.7 to 18.1
*Australia: New South Wales.
†Canada: Alberta and Manitoba.
‡Sweden: Uppsala-Örebro and Stockholm-Gotland health regions.
§UK (TNM analysis): West Midlands Cancer Intelligence Unit Eastern Cancer Registration and Information Centre in England and Northern Ireland; UK (SEER analysis): Northern Ireland.
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differences between the New South Wales coding scheme and
SEER could explain why New South Wales has an apparently
higher proportion of localised disease than elsewhere (eg, the
distance of main stem bronchial tumours from the carina is not
considered in the New South Wales system whereas it is in
SEER). This down-staging in New South Wales produces lower
stage-speciﬁc survival because their localised disease category
includes some patients who would be classiﬁed as having a more
advanced stage within SEER. We have detailed the potential
misclassiﬁcation when mapping T, N and M data to SEER and
have made recommendations on the coding of stage at diagnosis
for international surveillance of cancer control.16
Differences in the thoroughness of staging may also
contribute to international variation in stage distributions and
stage-speciﬁc survival. The proportion of histologically-
veriﬁed tumours varied widely, from 74.0% in the UK to
94.8% in Sweden. The high proportion in Sweden was consist-
ent with published estimates,23 and lower levels of histological
veriﬁcation in the UK are also well known, with mounting
evidence that elderly patients are much less likely to undergo
these invasive procedures in the UK due to concerns about
their frailty.24
Low stage-speciﬁc survival in the UK could conceivably
arise in part because of suboptimal staging, and this misclassi-
ﬁcation of stage in a proportion of patients could lead to
inappropriate treatment and therefore overall lower survival.
In order to understand the impact of different staging proce-
dures on international differences in survival, cancer registries
will need to capture information on the staging procedures
used for each patient—for example, whether sensitive investi-
gations such as positron emission tomography (PET)-CT were
used—enabling patients with very low volume metastatic
NSCLC to be correctly identiﬁed as having advanced disease,
or whether liver function tests were used to identify advanced
stage SCLC. At the very least, registries should record
whether the recorded stage was deﬁned clinically (based on
physical examination, imaging or endoscopy) or following
histological examination.
Stage data were missing for 2–43% of patients, despite restric-
tion to those registries where at least 50% of patients were
staged. Patients with missing data on stage tended to be older
and to have poorer survival than staged patients. To reduce bias,
we imputed stage where it was missing, using the available
covariables.19
Figure 3 Age-standardised excess
hazard (per 1000 person-years, log
scale) from small cell lung cancer by
stage, country and time since
diagnosis: TNM stage (upper panel)
and SEER Summary Stage 2000 (lower
panel). Notes: (1) National data are
used for Denmark and Norway. Other
countries are represented by regional
registries (Australia: New South Wales;
Canada: Alberta and Manitoba;
Sweden: Uppsala-Örebro and
Stockholm-Gotland health regions; the
UK (TNM analysis): West Midlands
Cancer Intelligence Unit, the Eastern
Cancer Registration and Information
Centre in England and Northern
Ireland; the UK (SEER analysis):
Northern Ireland). (2) Bubbles are
scaled to represent stage distribution
at diagnosis.
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We used standard approaches to deal with other potential
biases that face all international comparisons of cancer survival
using population-based data, such as age standardisation to
control for differences in the age distribution.25 Nonetheless,
some compositional differences remained: men made up over
59% of the patients in Australia, Norway and the UK compared
with less than 54% elsewhere, and men generally have lower
lung cancer survival than women.26 The histological subtypes of
lung cancer also varied. Non-microscopically veriﬁed cancers
were grouped with NSCLC, but those could have included
some patients with SCLC or misdiagnosed cancer. Any effect
would have been small, but probably more important in the UK
which had the lowest proportion of patients with histological
conﬁrmation (74.0%). The UK also had the lowest proportion
of adenocarcinomas, which have a better prognosis, and this
was true even after imputing morphology where it was missing
(results not shown).
In general, the completeness of all these registries is high, but
small differences in information capture could also contribute to
differences in survival. In Sweden, cancer registrations are not
initiated from death certiﬁcates as they are elsewhere, which
may mean some patients with very poor survival are missed.
The effect on overall survival will be minimal given the very
high completeness of the Swedish data.27
Despite these issues of data quality and comparability, there
remains evidence of large international differences in lung
cancer survival. For NSCLC, the low survival in Denmark is
driven partly by more advanced stage at diagnosis. In the UK,
the proportion of patients diagnosed at an early stage is also
lower than elsewhere. A more advanced stage distribution may
arise because of faster disease progression (possibly related to a
higher incidence of smoking28) or because of delays in diagno-
sis. Research has pointed to diagnostic delay in Denmark,13 29
and policies are now in place in Denmark and the UK to
shorten the time to diagnosis.29 30
However, survival from NSCLC in the UK was also compara-
tively low for each stage of disease. Compared with Sweden,
1-year survival in the UK was statistically signiﬁcantly 10–16%
lower within each TNM stage I–IV and 9–19% lower than in
Canada for stages I–III (survival for stage IV was low in
Canada). Danish patients had low stage-speciﬁc survival for
TNM stages I–II.
Patients in the UK also had lower overall survival from SCLC
despite the relatively favourable stage distribution, because
stage-speciﬁc survival at each stage was generally lower than
elsewhere.
Low stage-speciﬁc survival may indicate poorer levels of stage-
speciﬁc treatment. Previous studies have shown that surgery for
lung cancer is less frequently performed in the UK31 32 than
elsewhere in Europe33 34 or Canada.20 35 Similarly, lower provi-
sion of chemotherapy and radiotherapy has been reported in
the UK32 than in Australia,36 Canada20 and Sweden.34 These
studies are not directly comparable because they use different
methods, data and calendar periods. The overall pattern is
nevertheless suggestive of the need for wider access to optimal
treatment.
We are currently examining how far differences in treatment
between the six ICBP countries may explain the variation in sur-
vival. Other explanations that may be considered include
factors such as obesity, smoking, performance status and
comorbidity. It would be desirable to have data on these factors,
which may be more common in the countries with lower overall
survival,33 but such factors would have to be both highly preva-
lent and powerfully prognostic to explain the survival differ-
ences between countries reported here. Clinical choices may
also be more conservative in some countries than others in the
face of comorbidities, older age and lower performance status.
This study demonstrates wide differences between six
wealthy countries in short-term survival from lung cancer, the
most common cause of cancer death worldwide. These differ-
ences seem unlikely to be explained by artefacts of method or
unrecorded confounders, and differences in stage at diagnosis
and stage-speciﬁc treatment are likely to be important
explanations.
The study also shows the importance of including stage at
diagnosis in international survival comparisons. It is essential that
the quality, completeness and comparability of stage data are
improved, both in clinical settings and in population-based cancer
registries, in order to facilitate surveillance of international trends
in survival. Such comparisons incentivise policy development and
act as benchmarks for setting national cancer plans.
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analysis): Northern Ireland.
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